Cabazitaxel in Asian Patients With Advanced Gastric Cancer Who Failed Prior Chemotherapy

Inclusion criteria: * Histologically or cytologically confirmed unresectable or metastatic gastric adenocarcinoma including adenocarcinoma of gastroesophageal junction, which have failed 2 prior chemotherapy regimens. (For countries where a standard of care has not been established for the 2nd line treatment for advanced gastric cancer, those who failed 1 or 2 prior chemotherapy regimens can be included) * Signed informed consent Exclusion criteria: * Patients who have received \>2 prior systemic chemotherapy regimens for advanced gastric cancer. * For patients entering part 2, those without at least one measurable lesion at baseline according to Response Evaluation Criteria in Solid Tumors 1.1 criteria * Eastern Cooperative Oncology Group performance status \>1 * Age \<18 years * Inadequate organ and bone marrow function * Prior surgery, chemotherapy, targeted agents, investigational agents, or other anti-cancer therapy within 4 weeks prior to enrollment in the study * Prior radiation therapy within 6 weeks prior to enrollment (except palliative radiation for a local pain control) * Previous treatment with cabazitaxel * Known brain or leptomeningeal involvement of cancer * Patients with known acquired immunodeficiency syndrome (AIDS) related illness or known HIV infection requiring antiretroviral treatment. * Patients with active varicella zoster infection, or known hepatitis B or C infection. * History of severe hypersensitivity reaction ≥ grade 3 to drugs formulated with polysorbate 80 such as docetaxel The above information is not intended to contain all considerations relevant to a patient's potential participation in a clinical trial.